Adicet Bio, Inc. Stock price

Equities

ACET

US0070021086

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:06:37 2024-03-28 am EDT 5-day change 1st Jan Change
2.33 USD 0.00% Intraday chart for Adicet Bio, Inc. +13.67% +22.69%
Sales 2024 * - Sales 2025 * 3.57M Capitalization 191M
Net income 2024 * -122M Net income 2025 * -125M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 53.6 x
P/E ratio 2024 *
-1.27 x
P/E ratio 2025 *
-1.24 x
Employees 143
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.58%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Adicet Bio, Inc.

1 week+13.67%
Current month-1.32%
1 month-0.48%
3 months+33.27%
6 months+63.30%
Current year+22.69%
More quotes
1 week
2.02
Extreme 2.02
2.38
1 month
1.88
Extreme 1.88
2.54
Current year
1.75
Extreme 1.75
3.77
1 year
1.10
Extreme 1.1
7.50
3 years
1.10
Extreme 1.1
21.87
5 years
1.10
Extreme 1.1
21.87
10 years
1.10
Extreme 1.1
21.87
More quotes
Managers TitleAgeSince
Founder 71 14-10-31
Chief Executive Officer 51 16-06-30
Director of Finance/CFO 63 20-08-31
Members of the board TitleAgeSince
Director/Board Member 70 20-09-14
Chairman 59 15-08-14
Director/Board Member 64 21-11-16
More insiders
Date Price Change Volume
24-03-28 2.319 -0.48% 29 183
24-03-27 2.33 +4.02% 614,658
24-03-26 2.24 +1.82% 804,997
24-03-25 2.2 +0.46% 645,392
24-03-22 2.19 +7.35% 944,774

Delayed Quote Nasdaq, March 28, 2024 at 09:51 am EDT

More quotes
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.33 USD
Average target price
9.6 USD
Spread / Average Target
+312.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Adicet Bio, Inc. - Nasdaq